Grifols

Grifols Net Debt / EBITDA

The Net Debt to EBITDA of Grifols (GRF.MC) as of Nov 2, 2026 is 6.37. In the previous year, Net Debt to EBITDA was 6.96 — a change of -8.52% (lower).

Net Debt / EBITDA

6.37

YoY

-8.52%

Last updated:

Net Debt to EBITDA of Grifols is 2025 6.37 . Net Debt to EBITDA of Grifols was 2024 6.96 . It decreases by -8.52% lower compared to the previous year.

The Grifols Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
4.88 EUR
Jan 1, 2019
3.15 EUR
Jan 1, 2020
5.96 EUR
Jan 1, 2021
9.39 EUR
Jan 1, 2022
10.80 EUR
Jan 1, 2023
10.41 EUR
Jan 1, 2024
6.96 EUR
Jan 1, 2025
6.37 EUR
The Grifols Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
6.37-8.52%
6.96-33.12%
10.41-3.64%
10.80+15.04%
9.39+57.65%
5.96+89.12%
3.15-35.41%
4.88+0.41%
4.86+23.45%
3.93+14.16%
3.45+3.90%
3.32+34.92%
2.46-23.11%
3.20-65.22%
9.19+410.32%
1.80+28.15%
1.41-36.08%
2.20-6.60%
2.35-16.30%
2.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Grifols Stock analysis

What does Grifols do? Grifols SA is a globally operating company specialized in the manufacture and marketing of medical products and technologies. The company is headquartered in Barcelona, Spain and has been in existence for over 75 years. Grifols focuses on improving the quality of life through the production and marketing of blood products and services, diagnostics, and hospital pharmaceuticals. It has four main business areas: Bioscience, Hospital, Diagnostic, and Bio Supplies. Grifols emphasizes research and development to meet customer needs. It has introduced various products, including AlfaBIO, Vistogard, ID Core XT, NEO Blood Bank, and MIRASOL Pathogen Reduction Technology. Grifols is committed to innovation and quality, providing products and services that cater to a wide range of customers. Additionally, it is a significant employer in the biotechnology industry and contributes to economic development in different regions. Grifols is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Grifols stock

Net Debt to EBITDA of Grifols is 6.37 in 2025.

Net Debt to EBITDA of Grifols changed from 6.96 to 6.37, representing a -8.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Grifols since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Grifols with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Grifols

All Key Metrics — Grifols